L3VLUP
ProSign in

AGIO · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AGIOJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AGIO
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterAGIOJNJ
Q3 20209 holders, $371m30 holders, $26.2bn
Q4 20209 holders, $441m32 holders, $26.6bn
Q1 20219 holders, $483m31 holders, $25.3bn
Q2 20216 holders, $892m37 holders, $25.6bn
Q3 20216 holders, $283m40 holders, $24.1bn
Q4 20215 holders, $220m33 holders, $25.2bn
Q1 20227 holders, $203m35 holders, $28.2bn
Q2 20225 holders, $40m33 holders, $26.9bn
Q3 20227 holders, $198m36 holders, $25.4bn
Q4 20226 holders, $218m35 holders, $27.6bn
Q1 20235 holders, $186m42 holders, $24.5bn
Q2 20234 holders, $251m38 holders, $25.0bn
Q3 20234 holders, $205m37 holders, $18.9bn
Q4 20233 holders, $106m31 holders, $19.0bn
Q1 20245 holders, $180m32 holders, $19.7bn
Q2 202410 holders, $358m35 holders, $20.4bn
Q3 20246 holders, $332m28 holders, $22.3bn
Q4 20244 holders, $206m37 holders, $20.4bn
Q1 20253 holders, $181m32 holders, $20.5bn
Q2 20254 holders, $215m31 holders, $18.4bn
Q3 20253 holders, $250m32 holders, $23.7bn
Q4 20254 holders, $159m29 holders, $27.8bn
Q1 20265 holders, $306m34 holders, $35.6bn
Q2 20264 holders, $354m33 holders, $39.1bn
AGIO

Agios Pharmaceuticals Inc

Holders
3
Reported value
$250m
Buyers
2
Sellers
1

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only AGIO (3)

Artisan Partners LP, Farallon Capital Management LLC, Moore Capital Management LP

Only JNJ (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →